mAbxience acquires 100% of Genhelix

June 12, 2014 1:37 PM

mAbxience, a global company specialised in biosimilar medicines that belongs to Spanish-based Chemo Group, has purchased 100% of the Genhelix biopharmaceutical plant located in Spain.

The operation is one of the biggest investments ever made by a Spanish company in a biotechnology project.

mAbxience, a company working on biosimilar monoclonal antibodies, has an ambitious investment plan in the new plant to increase its capacity up to 16,000 litres in the coming years.

“Our aim is to expand our manufacturing capacities to strengthen our market presence in Europe and Asia”, asserted Hugo Sigman, CEO of the Insud Group and founder of Chemo.

Genhelix received in July 2013 the GMP approval by the European Authorities as a manufacturer of Biological APIs of its flexible and fully single use technology based facility. Genhelix is one of the few companies to receive such authorization at EU level and pioneer in being validated for a plant based on the most advanced technology components for single use.

“The acquisition of Genhelix is very important news in terms of consolidating mAbxience as a biosimilar medicines leader in Europe, and it will allow us to move forward in our strategy for manufacturing products that meet the highest quality standards and for obtaining significant cost savings”, declared Carlos Bañado, Managing Director of mAbxience.

Source: mAbxience press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!